ALK and central nervous system neoplasm: Strong antitumor effects have been demonstrated in tumor xenograft models derived from genetically engineered cells overexpressing ALK rearrangements, ROS1+ rearrangements, or crizotinib-resistant ALK and ROS1 mutations, as well as in CNS tumor models (Xia et al., 2021).